Gainers
- GH Research (NASDAQ:GHRS) shares rose 27.4% to $13.5 during Monday's pre-market session. The market value of their outstanding shares is at $702.3 million.
- HCW Biologics (NASDAQ:HCWB) shares rose 25.08% to $0.35. The market value of their outstanding shares is at $15.5 million.
- Invivyd (NASDAQ:IVVD) shares moved upwards by 23.0% to $0.44. The market value of their outstanding shares is at $52.6 million.
- ProPhase Labs (NASDAQ:PRPH) shares moved upwards by 21.95% to $0.32. The market value of their outstanding shares is at $9.7 million.
- Universe Pharmaceuticals (NASDAQ:UPC) shares moved upwards by 15.06% to $0.47. The company's market cap stands at $4.0 million.
- Cutera (NASDAQ:CUTR) stock rose 14.29% to $0.49. The company's market cap stands at $9.8 million.
Losers
- Viracta Therapeutics (NASDAQ:VIRX) shares fell 45.3% to $0.08 during Monday's pre-market session. The market value of their outstanding shares is at $3.2 million.
- AirSculpt Technologies (NASDAQ:AIRS) shares fell 16.29% to $4.01. The company's market cap stands at $232.1 million.
- Annovis Bio (NYSE:ANVS) shares decreased by 14.79% to $4.15. The company's market cap stands at $57.2 million.
- icad (NASDAQ:ICAD) stock fell 14.38% to $2.74. The market value of their outstanding shares is at $72.2 million.
- Nuvectis Pharma (NASDAQ:NVCT) stock fell 13.17% to $5.87. The market value of their outstanding shares is at $113.4 million.
- Orchestra BioMed Hldgs (NASDAQ:OBIO) stock fell 12.22% to $4.6. The market value of their outstanding shares is at $173.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
ANVSAnnovis Bio Inc
$1.98-8.76%
GHRSGH Research PLC
$12.76-%
HCWBHCW Biologics Inc
$3.90-1.20%
IVVDInvivyd Inc
$1.86-8.82%
NVCTNuvectis Pharma Inc
$5.92-1.66%
OBIOOrchestra BioMed Holdings Inc
$3.86-0.77%
PRPHProPhase Labs Inc
$0.3954-22.6%
UPCUniverse Pharmaceuticals Inc
$4.81-8.38%
VIRXViracta Therapeutics Inc
$0.00978-%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.